Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA questions higher rates of infection seen with highly anticipated Amgen osteoporosis drug
FDA questions higher rates of infection seen with highly anticipated Amgen osteoporosis drug
FDA questions higher rates of infection seen with highly anticipated Amgen osteoporosis drug
Submitted by
admin
on August 11, 2009 - 4:08pm
Source:
Yahoo/AP
News Tags:
FDA
Amgen
denosumab
osteoporosis
Headline:
FDA questions higher rates of infection seen with highly anticipated Amgen osteoporosis drug
Do Not Allow Advertisers to Use My Personal information
